Spicer J, et al.Clinical outcomes with neoadjuvant nivolumab (N) + chemotherapy (C) vs C by definitive surgery in patients (pts) with resectable NSCLC: 3-y results from the phase 3 CheckMate 816 trial. Abstract 8521, 2023 ASCO. 常建华 教授 内科主任,医学博士,主任医师 中国医学科学院肿瘤医院...
Spicer J, et al.Clinical outcomes with neoadjuvant nivolumab (N) + chemotherapy (C) vs C by definitive surgery in patients (pts) with resectable NSCLC: 3-y results from the phase 3 CheckMate 816 trial. Abstract 8521, 2023 ASCO. 常建华 教授 内科主任,医学博士,主任医师 中国医学科学院肿瘤医院...
CheckMate-816研究:新辅助免疫治疗延长可切除NSCLC患者的无事件生存 2022美国癌症研究协会(AACR)年会发布了III期CheckMate-816试验(NCT02998528)的结果,与单独化疗作为可切除非小细胞肺癌(NSCLC)患者的新辅助治疗相比,纳武利尤单抗联合铂类双药化疗可显著改善无事件生存期(EFS)[1]。 随机、开放标签、III期CheckMa...
2022美国癌症研究协会(AACR)年会发布了III期CheckMate-816试验(NCT02998528)的结果,与单独化疗作为可切除非小细胞肺癌(NSCLC)患者的新辅助治疗相比,纳武利尤单抗联合铂类双药化疗可显著改善无事件生存期(EFS)[1]。 随机、开放标签、III期CheckMate-816试验招募了358名IB-IIIA、可手术的早期NSCLC患者,要求患者能够耐受安...
3. Girard N, Spicer J, Provencio M, et al. Nivolumab (NIVO) + platinum-doublet chemotherapy (chemo) vs chemo as neoadjuvant treatment for resectable (IB-IIIA) non-small cell lung cancer (NSCLC): Event-free survival (EFS) results from the phase 3 CheckMate 816 trial. Presented at: 2022...
根据2023 ASCO展示的CheckMate 816试验(NCT02998528)的探索性分析(摘要#8521),与单独化疗相比,可切除非小细胞肺癌患者通过新辅助纳武利尤单抗+化疗改善了临床结果,即使在未接受手术的患者中,也能看到数值的改善(未达到统计学意义),肿瘤瞭望邀请中国医学科学院肿瘤医院深圳医院常建华教授予以点评。
参考文献:1.Girard N, Spicer J, Provencio M, et al. Nivolumab (NIVO) + platinum-doublet chemotherapy (chemo) vs chemo as neoadjuvant treatment for resectable (IB-IIIA) non-small cell lung cancer (NSCLC): Event-free survival (EFS) results from the phase 3 CheckMate 816 trial.Presented at...
参考文献:1.Girard N, Spicer J, Provencio M, et al. Nivolumab (NIVO) + platinum-doublet chemotherapy (chemo) vs chemo as neoadjuvant treatment for resectable (IB-IIIA) non-small cell lung cancer (NSCLC): Event-free survival (EFS) results from the phase 3 CheckMate 816 trial.Presented at...
3. Results 3.1 Efficacy(Fig 2-3)(Table 1-2)(Fig A1) 3.2 Safety(Table A1-2) 4. Discussion(Table 3-4) —图表汇总— 2.1 Clinical Trial Design Fig 1Study diagram (including a summary of the statistical analysis plan SAP)—CheckMate 816. ...
参考文献:1.Girard N, Spicer J, Provencio M, et al. Nivolumab (NIVO) + platinum-doublet chemotherapy (chemo) vs chemo as neoadjuvant treatment for resectable (IB-IIIA) non-small cell lung cancer (NSCLC): Event-free survival (EFS) results from the phase 3 CheckMate 816 trial.Presented at...